VIVS Fundamental Analysis - VIVOSIM LABS INC

Name: VIVOSIM LABS INC (VIVS) Stock
Brand: VIVOSIM LABS INC
Rating: 3.5 (3 reviews)

Fundamental Rating

VIVS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. VIVS has a great financial health rating, but its profitability evaluates not so good. VIVS is not valued too expensively and it also shows a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

VIVS had positive earnings in the past year.

VIVS had a negative operating cash flow in the past year.

VIVS had negative earnings in each of the past 5 years.

In the past 5 years VIVS always reported negative operating cash flow.

1.2 Ratios

VIVS's Return On Assets of -16.59% is fine compared to the rest of the industry. VIVS outperforms 79.78% of its industry peers.

With an excellent Return On Equity value of -20.83%, VIVS belongs to the best of the industry, outperforming 83.52% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-16.59%
ROE	-20.83%
ROIC	N/A

ROA(3y)-111.01%

ROA(5y)-81.92%

ROE(3y)-181.24%

ROE(5y)-124.91%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of VIVS (97.89%) is better than 97.19% of its industry peers.

In the last couple of years the Gross Margin of VIVS has grown nicely.

The Profit Margin and Operating Margin are not available for VIVS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	97.89%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y2.58%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

VIVS does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for VIVS has been reduced compared to 1 year ago.

The number of shares outstanding for VIVS has been reduced compared to 5 years ago.

VIVS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -41.44, we must say that VIVS is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of VIVS (-41.44) is worse than 91.76% of its industry peers.

VIVS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-41.44

ROIC/WACCN/A

WACC8.65%

2.3 Liquidity

A Current Ratio of 4.52 indicates that VIVS has no problem at all paying its short term obligations.

VIVS's Current ratio of 4.52 is in line compared to the rest of the industry. VIVS outperforms 50.00% of its industry peers.

VIVS has a Quick Ratio of 4.52. This indicates that VIVS is financially healthy and has no problem in meeting its short term obligations.

With a Quick ratio value of 4.52, VIVS perfoms like the industry average, outperforming 51.31% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	4.52
Quick Ratio	4.52

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

VIVS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 297.92%, which is quite impressive.

The Revenue has grown by 94.52% in the past year. This is a very strong growth!

The Revenue for VIVS have been decreasing by -42.03% on average. This is quite bad

EPS 1Y (TTM)297.92%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-397.81%

Revenue 1Y (TTM)94.52%

Revenue growth 3Y-54.21%

Revenue growth 5Y-42.03%

Sales Q2Q%-5.13%

3.2 Future

The Earnings Per Share is expected to decrease by -6.30% on average over the next years.

The Revenue is expected to grow by 16.82% on average over the next years. This is quite good.

EPS Next Y2.6%

EPS Next 2Y-6.3%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year18.24%

Revenue Next 2Y16.82%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

VIVS is valuated cheaply with a Price/Earnings ratio of 0.83.

VIVS's Price/Earnings ratio is rather cheap when compared to the industry. VIVS is cheaper than 99.81% of the companies in the same industry.

When comparing the Price/Earnings ratio of VIVS to the average of the S&P500 Index (27.08), we can say VIVS is valued rather cheaply.

VIVS is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	0.83
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

VIVS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

VIVS's earnings are expected to decrease with -6.30% in the coming years. This may justify a cheaper valuation.

PEG (NY)0.32

PEG (5Y)N/A

EPS Next 2Y-6.3%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

VIVS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

VIVOSIM LABS INC

NASDAQ:VIVS (10/28/2025, 4:30:02 PM)

2.28

-0.01 (-0.44%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)02-19 2025-02-19/bmo

Earnings (Next)N/A N/A

Inst Owners5.07%

Inst Owner ChangeN/A

Ins Owners0.6%

Ins Owner ChangeN/A

Market Cap5.93M

Revenue(TTM)142.00K

Net Income(TTM)-1987000

Analysts45.71

Price TargetN/A

Short Float %2.8%

Short Ratio0.18

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)-7.06%

Min Revenue beat(2)-22.82%

Max Revenue beat(2)8.7%

Revenue beat(4)1

Avg Revenue beat(4)-22.23%

Min Revenue beat(4)-46.52%

Max Revenue beat(4)8.7%

Revenue beat(8)2

Avg Revenue beat(8)-39.63%

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	0.83
Fwd PE	N/A
P/S	41.75
P/FCF	N/A
P/OCF	N/A
P/B	0.62
P/tB	0.62
EV/EBITDA	N/A

EPS(TTM)2.75

EY120.61%

EPS(NY)-0.89

Fwd EYN/A

FCF(TTM)-4.01

FCFYN/A

OCF(TTM)-4.01

OCFYN/A

SpS0.05

BVpS3.67

TBVpS3.67

PEG (NY)0.32

PEG (5Y)N/A

Graham Number15.07

Profitability

		Industry Rank	Sector Rank
ROA	-16.59%
ROE	-20.83%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	97.89%
FCFM	N/A

ROA(3y)-111.01%

ROA(5y)-81.92%

ROE(3y)-181.24%

ROE(5y)-124.91%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y2.58%

F-Score5

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.52
Quick Ratio	4.52
Altman-Z	-41.44

F-Score5

WACC8.65%

ROIC/WACCN/A

Cap/Depr(3y)52.61%

Cap/Depr(5y)295.14%

Cap/Sales(3y)51.89%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)297.92%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-397.81%

EPS Next Y2.6%

EPS Next 2Y-6.3%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)94.52%

Revenue growth 3Y-54.21%

Revenue growth 5Y-42.03%

Sales Q2Q%-5.13%

Revenue Next Year18.24%

Revenue Next 2Y16.82%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y14.96%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y33.39%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y31.95%

OCF growth 3YN/A

OCF growth 5YN/A

VIVOSIM LABS INC / VIVS FAQ

What is the ChartMill fundamental rating of VIVOSIM LABS INC (VIVS) stock?

ChartMill assigns a fundamental rating of 4 / 10 to VIVS.

What is the valuation status for VIVS stock?

ChartMill assigns a valuation rating of 4 / 10 to VIVOSIM LABS INC (VIVS). This can be considered as Fairly Valued.

What is the profitability of VIVS stock?

VIVOSIM LABS INC (VIVS) has a profitability rating of 3 / 10.

Can you provide the financial health for VIVS stock?

The financial health rating of VIVOSIM LABS INC (VIVS) is 7 / 10.

VIVOSIM LABS INC (VIVS) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

VIVOSIM LABS INC / VIVS FAQ

What is the ChartMill fundamental rating of VIVOSIM LABS INC (VIVS) stock?

What is the valuation status for VIVS stock?

What is the profitability of VIVS stock?

Can you provide the financial health for VIVS stock?